Gritstone bio is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. Co. discovers, develops, manufactures, and delivers cancer and infectious disease immunotherapy candidates by utilizing both of its vaccine vectors, self-amplifying mRNA and chimpanzee adenovirus. Co.'s oncology programs in clinical stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. Co.'s programs in clinical stage development are: CORAL, a second generation COVID-19 vaccine program and an HIV therapeutic/cure vaccine candidate that Co. is collaborating on with Gilead Sciences, Inc. The GRTS stock yearly return is shown above.
The yearly return on the GRTS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GRTS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|